New treatment yields complete regression of a human cancer in mice

April 23, 2007

A simple modification in an anti-cancer treatment currently in clinical trials substantially improves the drug’s effectiveness and reduces side effects in experiments with laboratory mice, researchers are reporting in an article scheduled for the May 16 edition of ACS’ Bioconjugate Chemistry. Enzon Pharmaceuticals’ David Filpula and colleagues at the National Cancer Institute worked on SS1P, a so-called immunotoxin that targets and destroys cells producing the surface protein mesothelin.

Ovarian, pancreatic and malignant mesothelioma cells all produce abnormally large amounts of mesothelin and thus are targets for SS1P. In the new study, researchers modified SS1P with PEGylation, which involves attaching chains of polyethylene glycol (also known as PEG) to the molecule. PEGylation is a well-established process that is used in at least six protein-based pharmaceutical products currently on the market.

PEGylated SS1Ps had fewer side effects and were more effective in mice bearing human tumors than standard SS1P, the report states. A single dose of the modified SS1P resulted in complete regression of the mouse tumors, the first time that such an effect had been observed, the researchers said. PEGylation of SS1P and other immunotoxins may hold promise for use in cancer patients, as well, they added.

Source: ACS

Related Stories

Recommended for you

Video: A colorful 'landing' on Pluto

January 20, 2017

What would it be like to actually land on Pluto? This movie was made from more than 100 images taken by NASA's New Horizons spacecraft over six weeks of approach and close flyby in the summer of 2015. The video offers a trip ...

Humans, not climate change, wiped out Australian megafauna

January 20, 2017

New evidence involving the ancient poop of some of the huge and astonishing creatures that once roamed Australia indicates the primary cause of their extinction around 45,000 years ago was likely a result of humans, not climate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.